Kevin Joseph Fitzgerald, CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 496 shares at $239.18 ($120K) on 2025-02-28, disclosed to the SEC on 2025-03-03.
Open-market sale of $120k ALNY by CSO & EVP, Head of Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $236.51 | 27 | $6K | 5.3% |
| 2 | $238.33 | 21 | $5K | 4.2% |
| 3 | $239.18 | 22 | $5K | 4.4% |
| 4 | $240.32 | 48 | $12K | 9.6% |
| 5 | $241.51 | 79 | $19K | 15.9% |
| 6 | $242.44 | 187 |
| $45K |
| 37.8% |
| 7 | $243.23 | 75 | $18K | 15.2% |
| 8 | $244.11 | 37 | $9K | 7.5% |
| Total | $241.69 avg | 496 | $120K | 100% |
| Filing → |
| ALNY | SELL | 2026-02-17 | $1.3M | — | Filing → |
| ALNY | SELL | 2026-01-14 | $1.4M | — | Filing → |
| ALNY | SELL | 2025-11-19 | $7.1M | — | Filing → |